By conjugating drugs to the dendrimer periphery via peptide linkers that are susceptible to cleavage by enzymes overexpressed in the tumor microenvironment (e.g., cathepsin B cleaving the Gly-Phe-Leu-Gly sequence), controlled drug release specifically at the tumor site can be achieved [32]. The gene discussed is CTSB; the disease is neoplasm.